CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have ...
Phase 2
The Bronx, New York, United States and 19 other locations
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic d...
Phase 2
New York, New York, United States and 22 other locations
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Phase 2
New York, New York, United States and 39 other locations
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic derm...
Phase 1
New York, New York, United States and 16 other locations
the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...
Phase 2
Kew Gardens, New York, United States of America and 21 other locations
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Phase 2
New York, New York, United States and 84 other locations
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Phase 2
East Syracuse, New York, United States and 26 other locations
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to a...
Phase 1
Fair Lawn, New Jersey, United States and 1 other location
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 2...
Phase 3
New York, New York, United States and 47 other locations
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...
Phase 3
East Windsor, New Jersey, United States of America and 88 other locations
Clinical trials
Research sites
Resources
Legal